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Abstract
Background: Human epidermal growth factor receptor-2 (HER2) is regarded as an important and promising target
in the treatment of HER2-positive breast cancers. However, the correlation of clinicopathological characteristics and
prognostic significance of HER2 overexpression in gastric cancer patients remains unclear. Our aim was to clarify
this issue.
Methods: Embase, PubMed, and the Cochrane Library were searched for relevant articles published up to May
2016. Outcomes of interest contained sex, age, tumor size, tumor site, tumor node metastasis (TNM) stage, distant
metastasis, lymph node metastasis, Lauren’s classification, differentiation grade, lymphovascular invasion, neural
invasion, and multivariate analysis data for overall survival.
Results: A total of 41 studies of 17,494 gastric cancer patients were identified with HER2 test. HER2 positive rate was 19.
07% (95% CI = 9.16, 28.98). There existed statistical significance between HER2 overexpression and patients’ prognosis
(RR = 1.47, 95% CI = 1.09, 1.98). Male patients (OR = 1.48, 95% CI = 1.34, 1.65), proximal tumors (OR = 1.25, 95%
CI = 1.07, 1.47), intestinal-type tumors (OR = 3.37, 95% CI = 2.54, 4.47), advanced stage cancers (OR = 1.35, 95%
CI = 1.10, 1.66), lymph node metastasis (OR = 1.26, 95% CI = 1.14, 1.41), well-differentiated cancers (OR = 1.79,
95% CI = 1.15, 2.76), and distant metastasis (OR = 1.91, 95% CI = 1.08, 3.38) were correlated with higher HER2
expression rates. However, no statistical differences existed in age, tumor size, lymphovascular invasion, or
neural invasion. Subgroup analysis revealed that HER2 expression rates reported in articles from Asian (19.52%)
countries were quantitatively higher than those from European (16.91%) areas. Results were consistent with
those reports that define HER2 status according to trastuzumab for gastric cancer (ToGA) criteria.
Conclusion: This study showed that HER2 overexpression was associated with poor prognosis in gastric
cancer patients. HER2 positive rates may be associated with sex, tumor site, TNM staging system, distant
metastasis, lymph node metastasis, Lauren’s classification, and differentiation grade in gastric cancer patients.
The HER2 expression rate in Asians may be higher than that in Europeans. This study offers a convenient way
for doctors to select patients for relevant HER2 detection and following treatment.
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Background
The human epidermal growth factor receptor-2 (HER2)
protein is a 185-kDa transmembrane tyrosine kinase (TK)
receptor and a member of the epidermal growth factor re-
ceptor (EGFR) family [1, 2]. HER2 expression on tumor
cells can influence tumor cell proliferation, migration, dif-
ferentiation, apoptosis, and adhesion [3]. HER2 expression
has been found in gastric cancer. Inhibition of the HER2
receptor is a promising treatment target [4, 5] in breast
cancers. Trastuzumab is a monoclonal antibody which
specifically targets the HER2 protein by directly binding
to the extracellular domain of the receptor. A phase 3,
open-label randomized controlled trial showed that trastu-
zumab in combination with chemotherapy exhibits both
efficacy and safety for the first-line treatment of advanced
gastric cancer with expression of HER2 [6]. In addition, in
several clinical trials, trastuzumab in combination with
chemotherapy reveals promising antitumor activity with
manageable toxic effects [7–10]. Although the outcomes
are encouraging, HER2 positive rate in gastric cancer pa-
tients is quite low, which means that only a small sub-
group of patients can benefit from anti-HER2 target
therapy. In consideration of the low positive expression
rate of HER2 and the expense of the HER2 examination
and anti-HER2 target therapy, therefore, selecting the
subgroup of patients with positive HER2 expression in
gastric cancer patients is of vital significance.
Recently, a number of studies reported the clinico-
pathological parameters and prognosis of HER2-positive
gastric cancers. Yet, the outcomes of these studies were
not uniform [11–15]. Therefore, we conducted a meta-
analysis to assess the association between the clinico-
pathological parameters and prognostic significance of
gastric cancer and HER2 expression by performing a
pooled analysis of the available literatures. Our aims
were to clarify the prognostic significance of HER2 ex-
pression and select those clinical parameters specific to
patients with gastric cancer expressing high levels of
HER2 to help physicians to select patients to undergo
more thorough HER2 detection.
Methods and materials
Search methods
Search of Embase, the Cochrane Library, and PubMed
for relevant articles published up to May 2016, with the
next search strategy: “human epidermal growth factor 2”
or “HER2” or “erbB-2” or “HER2/neu” combined with
“gastric cancer” or “gastric tumor” or “gastric carcin-
oma.” References of retrieved reviews were manually
screened to broaden the search range.
Inclusion and exclusion criteria with quality analysis
Eligible studies had to fulfill specific criteria to be
entered into this analysis. The inclusion criteria were (1)
gastric cancer patients; (2) the expression of HER2 was
tested by immunohistochemistry (IHC), chromogenic in
situ hybridization (CISH), or fluorescence in situ
hybridization (FISH); and (3) information on binary
clinicopathological factors according to HER2 status or
multivariate survival analysis data was provided. Exclu-
sion criteria were (1) conference abstracts, case reports,
letters, and reviews without primary data; (2) studies
from which relevant information could not be collected;
and (3) duplicated publications.
Assessment of study quality
To evaluate the quality of the final incorporated trials, two
investigators completed quality assessment independently
with the Newcastle–Ottawa quality assessment scale
(NOS) [16]. According to the NOS, studies were accessed
on three broad aspects: (1) selection of the study, (2) com-
parability of the cohort, and (3) confirmation of the out-
comes. Each item also has subitems. The full score was
nine stars, and any study that obtained five or more stars
was considered high quality [16].
Data extraction
Two independent investigators extracted the information
and, through discussion, decided on the basic characteristics
and variables to include. The following data were collected:
first author’s name, country, publication year, primary anti-
body, number of participants, HER2 expression rate, and
clinicopathological parameters stratified by HER2 status and
multivariate analysis data for overall survival.
Statistical analysis
Stata version 12.0 (Stata Corp, TX) was used to analyze
the data. Dichotomous variables were analyzed with
odds ratios (OR) and 95% confidence interval (CI). Risk
ratios (RR) and 95% CIs of between HER2+ and HER2−
were analyzed with random effects model. According to
heterogeneity, a random effects model or fixed effects
model was selected. I2 statistics was used to evaluate
heterogeneity [17]. I2 < 25% was considered low, and the
data was combined using a fixed effects model (the
Mantel–Haenszel method), while for I2 > 25%, a random
effects model (the DerSimonian and Laird method) was
performed for data combination. Sensitivity analysis was
conducted by removing individual trials from the list
and analyzing the degree of change on the overall results
to find out sources of heterogeneity. Publication bias
was evaluated by funnel plots. A P < 0.05 was regarded
to be significant statistical difference.
Results
Description of trials
A flow chart describing the process of study selection
based on the PRISMA statement (Checklist S1) was
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shown in Fig. 1 the QUOROM diagram. A final total of
41 articles [11–15, 18–53] of 17,494 participants were
included in our study. The basic characteristics of the
contained researches were reported in Additional file 1.
The details of NOS were described in Additional file 2.
Thirty-four Asian countries in our study were included,
and the HER2 positive rate was 19.52, (9.32, 29.72).
Seven studies of European countries reported the posi-
tive rate of HER2 was 16.91, (8.19, 25.63).
Association of HER2 expression and clinicopathological
parameters
The results of our study indicated that HER2 overex-
pression was associated with sex, tumor site, Lauren’s
classification, tumor node metastasis (TNM) stage,
lymph node metastasis, differentiation grade, and distant
metastasis. However, HER2 overexpression was not re-
lated to age, tumor size, lymphovascular invasion, or
neural invasion. The detailed information was shown in
Table 1.
Risk ratios on overall survival
Ten of 41 studies reported multivariate survival analysis in-
formation on overall survival (OS). Owing to significant het-
erogeneity, a random effects model was used to combine
the data as demonstrated in Fig. 2. The results showed that
HER2 overexpression was associated with a poor OS
(pooled RR 1.47, 95% CI 1.09–1.98). Significant heterogen-
eity existed between studies (I2 = 69.4%, P= 0.001).
Sensitivity analysis
Trials were removed individually from the list, and the
OR value or degree of significance did not substantially
change in regard to the risk ratios on overall survival,
age, sex, tumor size, tumor site, TNM stage, lymph node
metastasis, distant metastasis, differentiation grade,
Lauren’s classification, lymphovascular invasion, and
neural invasion.
Publication bias
To visually assess the publication bias of the researches,
funnel plots were performed. The shape of the funnel
plots showed symmetry and indicated no significant
publication bias (as shown in Fig. 3).
Subgroup analysis By stratifying the trials according to
HER2 status by Hoffman validation criteria [54], a fur-
ther subgroup analysis was conducted. The definition of
HER2 positive by Hoffman validation criteria was that
tumor samples were scored as 3+ on immunohistochem-
istry or if they were FISH positive (HER2:CEP17 ratio
≥2). The results obtained from the above analyses are
similar to that of the overall analysis (as shown in
Table 2).
Discussion
A meta-analysis was conducted to clarify the correlation
between clinicopathological characteristics and prognos-
tic significance of HER2 expression in gastric cancer pa-
tients. In current analysis, we included all available data
Records identified through 
database searching
(n = 3372)
Additional records identified 
through reference lists
(n =214)




Reviews or letters (n=8)
Data not available (n=6)
Not related to gastric cancer (n=1)
Full-text articles assessed fr eligibility
(n = 46)
Duplicated publications (n=5)
Studies included in qualitative synthesis
(n = 41)
Fig. 1 Procedure of study selection
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from 41 studies. This study showed that HER2 overex-
pression was associated with poor prognosis in gastric
cancer patients. We also found that gastric cancers in
male patients, at proximal sites, of intestinal type, in ad-
vanced stages, with lymph node metastasis, that are well
differentiated and that have distant metastasis, were
more likely to exhibit higher HER2 expression rates.
Through subgroup analysis, we also found that HER2
expression rates reported in articles from Asian coun-
tries were quantitatively higher than those from
European areas. The outcomes of incorporating articles
defining HER2 status according to Hoffman validation
criteria [6] are similar to that of the overall analysis
which indicates that our results are reliable.
HER2, a member of the epidermal growth factor re-
ceptor (EGFR) family, is correlated with tumor cell
proliferation, migration, differentiation, apoptosis, and
adhesion [1–3]. There is growing evidence that HER2
plays an important role in tumorigenesis in gastric can-
cer [55–57]. Our pooled analysis suggested that HER2
overexpression had played an unfavorable role in the
prognosis of gastric cancer. In addition, HER2 positive
rates were correlated with TNM stage, distant metasta-
sis, and lymph node metastasis which are consistent
with previous researches. Potential clinical benefits of
HER2 target therapy may be achieved in the adjuvant
treatment for gastric cancer patients with lymph node
metastasis and distant metastasis.
Advanced tumor biological behavior, such as distant
metastasis and lymph node metastasis, generally indi-
cates poor prognosis. Yet, the results of our pooled ana-
lysis indicated that HER2 expression is also strongly
Table 1 Association of HER2 expression and clinicopathological parameters
Clinicopathological parameters Number of studies Number of patients OR (95% CI) P Heterogeneity
I2 (%) P value
Age (old vs young) 27 12,800 0.90(0.74,1.10) 0.31 62.9 0.00
Sex (male vs female) 33 15,304 1.48(1.34,1.65) 0.00 21.1 0.14
Tumor size (large vs small) 11 1614 0.83(0.64,1.07) 0.21 13.4 0.32
Tumor site (proximal vs distal) 24 12,853 1.25(1.07,1.47) 0.01 27.4 0.11
Lauren’s classification (intestinal vs diffuse) 30 13,972 3.37(2.54,4.47) 0.00 74.2 0.00
TNM stage (III+IV vs I+II) 24 12,542 1.35(1.10,1.66) 0.01 62.4 0.00
Lymph node metastasis(N+ vs N−) 27 14,075 1.26(1.14,1.41) 0.03 0.0 0.66
Differentiation grade (well vs poor) 28 9086 1.79(1.15,2.76) 0.01 86.6 0.00
Distant metastasis (M+ vs M−) 9 4427 1.91(1.08,3.38) 0.00 54.4 0.03
Lymphovascular invasion (yes vs no) 10 3957 1.30(0.86,1.95) 0.22 62.5 0.00
Neural invasion (yes vs no) 4 1361 0.58(0.24,1.37) 0.21 80.1 0.00
OR odds ratio, CI confidence interval, N node, M metastasis
Fig. 2 Risk ratios (RRs) and 95% confidence intervals (CIs) in studies assessing the relationship between HER2 expression and overall survival (OS)
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related to intestinal-type tumors and well-differentiated
gastric cancers, which usually have a better prognosis
than diffuse-type tumors or poorly differentiated
cancers. These seemingly conflicting observations lead
to debate regarding the prognostic significance of HER2
expression. The results of our pooled analysis are in
agreement with the outcome of the trastuzumab for
gastric cancer (ToGA) trial. The most likely explanation
may be that the expression of the HER2 protein in
intestinal-type gastric cancers accounts for a small part,
and this could not be the only factor included that im-
pacts prognosis [21]. Further researches are needed to
interpret this phenomenon.Our study found evidently
higher HER2 expression rate in proximal gastric cancers
than in distal ones, which was in agreement with the
report of the ToGA research [6]. Eric VC et al. suggested
that intestinal-type gastric cancers generally occurred
more frequently in proximal sites and that different eti-
ologies may play a role in carcinogenesis of cancers from
these two sites [58]. This could partly explain different
HER2 expression rates depending on tumor location.
Until now, studies exploring HER2 expression in gas-
tric cancers generated conflicting results regarding
HER2 expression and its association with clinicopatho-
logical parameters. Many factors could result in these in-
consistencies, but the most significant ones are most
likely the use of different IHC staining methods and the
application of inconsistent scoring criteria. Therefore,
we performed a subgroup analysis of the researches
based on HER2 status according to Hoffman validation
criteria, which is the standardized scoring system used
for HER2 expression [54]. The results drawn from the
subgroup analysis were similar to that of the overall ana-
lysis which indicates that our results are reliable.
The low percentage of HER2 expression in gastric can-
cer patients discourages doctors from detecting HER2
status before starting chemotherapy. In consideration of
the expense and side effects of anti-HER2 target therapy,
further exploration is necessary to select for those pa-
tients who are most likely have high levels of HER2 ex-
pression. The clarification of the association between
HER2 expression and gastric cancer clinicopathological
features offers a convenient way to select for patients
that are most likely to have a high level of HER2 expres-
sion. This provides principles by which to stratify pa-
tients in clinical practice. Our results indicate that
patients with advanced stage cancers, distant metastasis,
and lymph node metastasis tend to have higher levels of
HER2 expression. In addition, these clinicopathological
features were associated with aggressive stage cancers
and poor prognosis; therefore, our results rationalize the
Fig. 3 Funnel plot for ten studies included in multivariate analysis of
overall survival
Table 2 Subgroup analysis by defining HER2 status by Hoffman validation criteria
Not fit Hoffman criteria Fit Hoffman criteria





I2 (%) P value I2 (%) P value
Sex 18 1.34(1.15, 1.56) <0.001 0.0 0.716 15 1.63(1.41, 1.89) <0.001 42.4 0.042
Age 13 1.01(0.72, 1.41) 0.976 72.0 0.000 14 0.78(0.62, 0.99) 0.038 45.6 0.032
Tumor size 7 0.94(0.70, 1.26) 0.692 0.0 0.486 4 0.55(0.32, 0.96) 0.070 12.6 0.330
Tumor site 10 1.06(0.83, 1.37) 0.632 25.3 0.211 14 1.40(1.14, 1.71) 0.001 25.2 0.182
Lauren’s classification 17 3.67(2.47, 5.47) <0.001 76.2 <0.001 13 3.03(1.95,4.70) <0.001 73.4 <0.001
Differentiation grade 16 1.24(0.76, 2.05) 0.390 74.8 <0.001 12 2.71(1.66, 4.44) <0.001 76.8 <0.001
TNM stage (III+IV vs I+II) 14 1.53(1.05,2.23) 0.026 77.4 <0.001 10 1.23(1.04,1.46) 0.014 0.0 0.939
Lymph node metastasis 13 1.15(1.00, 1.33) 0.057 0.0 0.500 14 1.40(1.19, 1.64) <0.001 0.0 0.847
Distant metastasis 5 2.58(1.00, 6.67) 0.050 64.8 0.023 4 1.52(1.18, 1.95) 0.001 0.0 0.617
Lymphovascular invasion 6 1.18(0.75, 1.85) 0.468 74.1 0.002 4 2.16(0.87, 5.35) 0.096 0.0 0.421
Overall survival 4 1.95(1.38, 2.51) <0.001 0.0 0.583 6 1.11(0.68, 1.53) <0.001 70.8 0.004
OR odds ratio, CI confidence interval, TNM tumor, node, metastasis
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application of HER2-targeting therapy to patients with
advanced stage disease that lack effective alternatives.
Several limitations existed in our report. First, the cri-
teria of HER2 status determined by IHC and the primary
antibodies varied in studies. However, the results of the
studies defining HER2 status by Hoffman validation cri-
teria were similar to that of the overall analysis which in-
dicates that our results are reliable. Second, our results
indicated that HER2 overexpression was associated with
a poor prognosis. To our knowledge, many factors could
affect prognosis. Therefore, we incorporated only the
outcomes with the form of multivariate survival analysis
to eliminate the potential influence of confounders.
Third, biopsy specimen could not represent the whole
tumor tissue. Four studies included both resection speci-
men and biopsy specimen, and three researches did not
state in our meta-analysis (Additional file 1). Because
none of the included studies stated the details of HER2
expression both in resection specimen or biopsy speci-
men, we thus could not conduct a subgroup analysis on
this issue in the present meta-analyses. Further studies
should be conducted to clarify this issue. Fourth, our
study was confined to articles written in English, which
language bias could not be ruled out.
Conclusions
In conclusion, our study clarified that HER2 overexpres-
sion was associated with poor prognosis in gastric can-
cer patients. In addition, HER2 overexpression was
correlated with the following clinicopathological param-
eters in gastric cancer patients: sex, tumor site, TNM
stage, lymph node metastasis, distant metastasis, differ-
entiation grade, and Lauren’s classification. The HER2
expression rate in Asians may be higher than that in
Europeans. This study offers a convenient way for
doctors to select patients for relevant HER2 detection
and following treatment.
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